GIF89a̙fffff33333!,I8ͻ`(dihlp,tmx|pH,Ȥrl:ШtJZجvzxL.zn|N~@8V8 a%(T@  bĆJhȱcGnXH20dĉDTp2Lqi@I,*D$̣.Qit!|*4QB^TP@.jD FIBLmĺUHBک8jv&ֹC[C[v* $5zG[kpc<[W{.)HWњ> Jmםi!L/ V5&s mjdO ʓh(л˅"ݥ!Ye% QS 2xĀ{,4aUb$$'Ԅh\t C}enpc!z%g"E,=!IE% 85 gSS9VtS7UDԌSquImyC ȇ{]6g 1*l\3tfYۭPCXxOB=>RcP0Xפ^'9t]*\]O ,$1ex}{m9` :s[kfMhfL/'mmsQ){ PV@GQ.Ap[ws,:% oq^ f8!!|AE&Ƒx:ǿd)0 <]g:٭!PD۔z䁾du% FXv HDE%^xaULkF䈧 ix#c22L#ǶaF??T! :#{A!MPcJ>*rk$b١~:" ƞy/dF(HPNJ,SDK\eiL&ʯ ⢣0uD fy@i:N>#!xKeS@Y4,shyl6g&IRT,S πiAFz0ldP2iQxdk֣aw}O dW&}`GO̯ڔDYD {G"פW&)~w_T3A|_ΰv>Vmo{Q^{~|I:cFDa~Ok+D(y<ͨU/D m-,ؗi5"'vb#noҀ  &#7a(6؁ "8$X&x(*,؂.0284X6x8:<؃>@B8DXFxHJp6p00P(pSx^(U\(^XaQ؆ 0rZx`^hH=pȇ}Xp pH"`؈0i8px(`((؈g(Xx[؋V8~NxxxhfHH`xfHhx8X#؍"pe(Ũ ؈0˘XxqobvX昏:Hن)YI!iH&*#و'yh647lXؑs3)6)hF ؆<[M%ЈM\Kۚ ّ=f ]Cz9:0vXݜ <x+Aܾ,-? ڵ-:ߺm>=-]^Pι=ކKiн=a|}%omͬ\}MdMވ͝؋X|۬>n 1ۼߝ:C=xIĽ2( KN]D-Q-T>\l3,:ʪ ͈zm7+iI@ʚ=ms]\F N$톍౎ A^*$>W~(~n,ݞN|띭'!Rm>{=6@~X؍ˎ@ڶ՜ +©̎ŽH" pWmΉN ϑ=5(m︭⯞㘻Nϔu@~_=n>ۍo\OI~亮D-kI4 `ޮ'|+Т`-+9_1);ɲ.\Mi_}/,+)b1|Ժ:M}WH|_?*ƋǍ>m隖/yw?nv* SӦ_'UȌ-Wyc{ޏ# /Sdž*˯/U f&_5@ INYR}:6qԺ".q``shP>: {N? 0 *Ԣ 78KQ0ACVk 1;"Bh"1̏(A(r4Dɯ[rdQ̚oBb)ѡ(o''2qчNLL(۠.\Ql,Ϝ <(O<LgEHb*4\Q`)DosV0U^etawTbZH6ZijsRtjlUT;-JaD#hs=3ZST^>Mw= |?WWlZ}V Wށ8a?9dG&dOF9eWfe_9fgfo9gwg:h&hF:ifi:jj:kk;l&lF;mfm߆;n离n;oox'xG>ygy矇>z駧z>{{?|'|G?}g}߇?~秿~?`8@ЀD`@6Ё`%8A VЂ`5Av(0 $"$@@(B@ @ &< BЃP@81ЁbBD"BD* 07V;TA*E,cи hшM<D3N'v3:t#S%‐Cǒ)RrDr1͑!XI@VQȣK"҉A$!p3~MDDv24m#YfRԘ8g8w~-.QMRG)Ѕ ?SCbPhyKG5XcP I.$pAI7B&3Ae$,EVke!L+6-3@Z-}0+TA8i(3ظ46e+c!63Pb@%ZZlD;ϴ"(%#)Y.+)8gdyT"#QEj 1߸MҀ$EyY $f9UG/nLmiMs=x}d _R%;̡u7[qKevmkdʒ:fiΙOΖh`m5=4yl2(@>$$%kbav~,=JчEu[m2oWߑerOg|Nh7S;us[5x q-j|3tі)r~y}[d#%Qƣ6v?>9ͩzm^<.Δ:ͫtO9oAӛX~ziF}~ܙ޷:7;s.y1v:vz$Gi'z3oUu y'Qݸ j?>ͯg}y_COϙ⛞_~@oG ZjOlyk'Ĩӿ3Y-c@#k:;{@D#[=Ż@_A2A?18C>9R83LӴփ7+)ۺKKq#B=J"@9$%\t!/8BBк/$@8A1-ϻ71ԂC l:,@@6t>k>*8,ړ맢BBH۩LӲJC0 $yK695 C#@Ck6B;I~*3N0F~:*,HBԵ#d/L;4EL*$lt9>$dEm>AD>WdU26ƛk<|GRܤbBo$@I@ GLJ%FC|ES0)):/iCoy\0CI|=w,I:s5W򥉫!lVşܙ2cJ& pJ*X9Yȧ<Z jİc8 G QT_;&k%Bh$BKCdozsCAƍ!qDǿ4\DADBry!ċGDȫ R˛K:2̉Qj0Œ~J4*Z&RIpL̏ 0͌۲dNB2̽5T-M@A#ܜ@HrMT<C#:[-+ν:NKW#ALLl&+PMDTPL̻9:$OF,DzO&-JS O 8ǤIѾf#>J# , 'M;"e3'<p*όPSZ/EC\UD*}EP[P8mQnPěBtS[m2XiVGq ˬM!L$@V]%H 'vC]ҖDЀeTA=Y#3T#Wye0(}-P|6.mS'MXdY&eMZ:0|%,yRZE"*Z#dNZژų$mIXE@Dm(8;YBK[O3S*uCGY`F&`ۼہfIdm#luB[l[T+\@QR$\[|ۇ5Eř)/Sݱ]Rr%U5b݈֕U%]kN]U\*YE:1K8%^٥ŞFpMQ$SPp]WAU_ *_z0BE_&6FVfv `‚_`C`=,EY!J{ݶ\LC ̚]¥PKX9VdŋeRJٱS1ӫIf ε+Ël LDmE#;؄j!$cݤUUM`7<6c,cqx$*3?K3^KO@. / I~G#E~hp t deLJݨv1K1h&GiR,vឭ\)3r,.⠤VUSbB";ElCc4FӰ:m&nE4ޮWmc>Lǫi T{Y0Qdv\L:BX.B=Xf\,*Eh/E\lo~, dTZ.FqjL..BDŽLklmײiMXiudR'SrRvXKaoŇk";e WUk˽r*vJQo*K޺>j-Jԋ%beFDM@(T̝b8Ϟqad$Q1n ĝї>"&n*\'\[eO#[VyNcH^y}<0/vzNfvUg=T ^R) NrVgbS%8C;_^sOUl%ORiK?TxaGuM&)-Z ˾V'zXtumO(> [HO*s&K2fWe+oVtBrIoovPz.VTOV5[ˣfs"~rfog3#mz{s->,p_%/VĔMj-u{2 婗ժOgeXI[dYJKaΨ++,@^B[F_@[`B^O% 'hhJ# Mœ ٭$ WT,)-Ei*ȳ١0ͩ`$qq`rr/H+pyh=z*\fB$R< 4җ"A(7x&#L^ `@Z E0lo&q@Р4zqG"ǒóL,KkPcTb^(KZW;Lx5MTyԔW3+~~MDYvIk5%bM-m ,͏%j\IM&\8퉊ZO^JVc":L@tn:Hc3 0 pF: Tkn08̱r̫(Kh"`A4h.+:4gyWC4 g_ШUĠ#[_}$a~<_HA]gbK{!WhWPgݍEb4rߎFj,JatɜW#{0E;\D$j t%Ywya -0\Xdz/963N>9qډ(7]Y7dYmhMlyjt*pW|#%諆nmXX!;Ԓ֧)~AhyİjaxrDh8Ydm**!81j)L##ZçWnhH,jZ[(*`)+畳{q5AO 8DEK ;,ԹA !&l*{šq O$|A ",BpO紤\hHDK9Iclء>]c1joq6mfku ν$M6yҦ"Gi'5;N"ۏK>9[~9kNy{9衋>:饋ҹ驫:뭻:(>;~;˞;;<<<;<1o[=={0?>>髿>>?????(< 2| #( R 3 r C(&!(!F<"%P2N|"()RV"-r^"(1f<#Ө5n|#(9ұv#=~# )A/;
Sunday, April 28th 2013

The Government Telling You What Drugs You Can Take Is A Balancing Act

What’s the substantial difference between hydrocodone or dihydromorphone or diacetylmorphine? Beyond their manmade designations. Their potential risks versus their potential benefits are difficult things to quantify. In some studies diacetylmorphine is a better analgesic than morphine; nowadays, at least in the United States, only the criminal can tell us anecdotally. The various governments of our federal republic nominally weigh the risk versus reward of all controlled substances in determining under what conditions they will allow them.

It is true that government regulatory behavior appears to influence clinical providers utilization of opiates. But considering physicians can’t even agree on the appropriate use of the opiates the government does lend them to use,

It is unlikely these standards will be developed until there is a consensus among pain specialists about opioid use for nonmalignant pain because boards/agencies have no consistent, reliable source of expert information: Pain specialists should initiate efforts to develop this consensus.

Long term opiates for nonmalignant chronic conditions remain a controversial subject. I say that despite their wide use. Many factors including many psychological and social and financial factors that favor benefit from opiates play into any improvement (or lack thereof) in such pain. And the long term benefit from opiates in a condition like chronic back pain is questionable at best despite the fact such drugs may be the only thing that seems to make your loved friend or family functional. To be fair, not as dubious as surgery itself often.

Nor, as above, is the utilization of opiates, even amongst pain specialists, standardized for such conditions. It is remarkable both the variations amongst clinicians in opiate use for nonmalignant pain and the factors that influence such use. So a belief your personal health care providers know best for your pain may be an inadequate argument against government regulation of opiates.

I’m not a fan of government regulation of opiates whether in a medical setting

My wife suffers from chronic pain…she…requires daily narcotic pain medication to manage her pain.

[...]

My wife is not the criminal. Colorado and the DEA are forcing her to live in pain as they restrict her legal access to pain relief. No one should have to watch the person they love suffer in unimaginable pain just because of bureaucratic hurdles put in place to slow illegal drug use.

…or for personal treatment or other reasons. The point of this post is the distinction is smaller than you may imagine. “[I]llegal drug use” is whatever the government says. Philosophically is there much difference between restricting the hours when you can get morphine from a pharmacy and making the very possession of heroin out of the lab illegal?

Share/Bookmark